VivoSeq
Other

BOS

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

BOS is an early-stage landscape with 0 programs across 4 companies. The most active players are Pfizer, Boehringer Ingelheim, Chengdu Kanghong Pharmaceutical Group Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalC

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Completed17 · 74%
Terminated3 · 13%
Unknown status2 · 9%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

23 trials

Subconjunctival Humira for Boston Keratoprosthesis
Not yet recruiting·MMassachusetts Eye and Ear Infirmary·Phase 1·NCT06926478·8 enrolled
Effect of Rifampin on Bosutinib When Both Are Given to Healthy People
Completed·Pfizer logoPfizer·Phase 1·NCT00725426·24 enrolled
DES Versus BiOSS LIM - POLBOS II Study
Completed·Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland·Phase 4·NCT02198300·202 enrolled
Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects
Completed·Pfizer logoPfizer·Phase 1·NCT00777530·48 enrolled
Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition
Completed·Pfizer logoPfizer·Phase 1·NCT04916769·18 enrolled
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
Completed·Ppharmaand GmbH·Phase 1·NCT01009190·85 enrolled
Absolute Bioavailability Of Bosutinib
Completed·Pfizer logoPfizer·Phase 1·NCT02192294·14 enrolled
Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions
Completed·Pfizer logoPfizer·Phase 1·NCT01080365·31 enrolled
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
Completed·Pfizer logoPfizer·N/A·NCT02546375·87 enrolled
Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects
Completed·Pfizer logoPfizer·Phase 1·NCT01374139·88 enrolled
The Safety and Tolerability of Pirfenidone for BOS After HCT
Completed·SStanford University·Phase 1·NCT03315741·30 enrolled
Japanese P III vs Voglibose and Placebo
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT00654381·561 enrolled
A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT07081932·16 enrolled
A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT05723874·14 enrolled
Safety of Bosentan in Type II Diabetic Patients
Completed·RRetinset SL·Phase 1·NCT04068272·22 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)